BioLargo Inc. (BLGO:OTCQX) announced that its subsidiary BioLargo Equipment Solutions & Technologies Inc. (BEST) was featured prominently for its advances in electrostatic PFAS treatment technology, according to a Dec. 3 press release in Chemical Engineering magazine.
The article, titled “Electrostatic PFAS Capture Produces Nearly Zero Waste,” highlights the benefits of BioLargo’s Aqueous Electrostatic Concentrator (AEC) platform, which effectively removes long-, short-, and ultra-short-chain PFAS while generating significantly less waste than traditional treatment methods.
Additionally, BioLargo has completed delivery of the final components of the AEC system purchased from Lake Stockholm Systems Inc. to the municipal drinking water treatment plant in Lake Stockholm, New Jersey. The team is on site and begins providing the necessary support to help the general contractor and customer deploy, integrate and commission the system.
“This milestone represents the final stage before AEC begins serving the Lake Stockholm community, and everyone is excited to get to work.” until completion the deployment phase until completion” said BEST President Tonya Chandler. “We are proud that our work is recognized by Chemical Engineering, and we are equally proud that we are helping to deliver affordable, PFAS-free water to the world.” The state of New Jersey is a leader in PFAS cleanup efforts. Recent pioneering settlements of more than the USA$2.5 billion between the State of New Jersey and major polluters enable solutions like our AEC to have an impact on the ground.”
Huge energy savings
In November, BioLargo announced a significant improvement to its patented AEC system, achieving over 90% reduction in energy consumption for large-scale “forever chemical” treatment of drinking water compared to previous AEC versions, according to a Nov. 3 press release.
This advancement is based on data from May 2025 that showed the AEC system can save up to 80% in total lifecycle costs compared to competitors Treatment methods like carbon Filtrationdue to its efficiency in capturing PFAS molecules and ease of handling PFAS-laden byproducts, the company explained.
This new energy reduction breakthrough enhances AEC's economic advantages over existing technologies, providing an industry-leading combination of cost effectiveness, energy performance and undetectable PFAS removal (less than 1 part per trillion) in both drinking water and brackish water sources.
“We solve PFAS treatment in the harshest field conditions,” Randall Moore, president of BioLargo Engineering, said at the time. “This breakthrough proves that scalable, energy-efficient PFAS removal is not only possible;It is ready for large-scale deployment.”
For a typical municipal system operating at 1,000 gallons per minute using previous generation AEC technology, the new AEC module can reduce monthly energy costs from approximately $208,000 to just $15,700, resulting in annual savings of more than $2.3 million at electricity rates of $0.15/kWh. Even for industrial waters with a higher total dissolved solids content than drinking water, the new AEC system achieved an 88% reduction in energy consumption, demonstrating its versatility and efficiency in various applications, BioLargo said in the press release.
“This is not just an incremental improvement. I“It is a transformational leap that makes large-scale PFAS treatment even more economical and environmentally sustainable,” said Dennis Calvert, President and Chief Executive Officer of BioLargo.
A “full-service” water treatment solution
BioLargo's AEC technology is extremely effective at removing per- and polyfluoroalkyl substances (PFAS), commonly known as “forever chemicals” and now regulated under the Safe Drinking Water Act.
With increasingly stringent state and federal regulations and ongoing lawsuits against polluters, there is a growing demand for reliable and cost-effective PFAS removal solutions. Calvert said the AEC technology is perfect for this regulatory environment due to its comprehensive ability to capture all types of PFAS tested, its minimal production of waste byproducts (which can increase costs and regulatory challenges for operators), and its cost-effectiveness compared to traditional methods such as carbon filtration.
BioLargo has developed a comprehensive, full-service water treatment solution that combines AEC technology with engineering design, field testing, installation, PFAS collection and destruction, and maintenance capabilities, providing customers with a true turnkey solution that can generate revenue for the company early in the project lifecycle.
Unlike high-pressure membranes or adsorption systems, the AEC platform uses low-voltage electrostatic separation to capture and concentrate PFAS without generating large waste streams, BioLargo said. It requires minimal maintenance, fewer filter changes and produces only 1/40,000th the waste of carbon filtration. BioLargo also offers integrated collection, destruction and disposal services for a complete PFAS solution.
Expert Is 'Hot' About Co's Long-Term Prospects
Chris Temple of The National Investor commented on the company following a recent announcement regarding AEC's effectiveness, saying, “BioLargo announced that its program to remove PFAS chemicals from water for good is even more robust.” Temple also mentioned his plans to visit the Energy Division in Oak Ridge, Tennessee, where the company is developing its new battery technology, in the coming weeks.
“I'm very interested in the long-term prospects of this company, despite the fact that pitfalls here and there have slowed down BioLargo's stock price somewhat,” Temple said in a Nov. 20 online interview with Calvert and the president of Clyra Medical Technologies, BioLargo subsidiary Clyra Medical Technologies. “We’ve had upswings and then setbacks a few times in the last year.”
Additionally, Oak Ridge Financial analyst Richard Ryan noted, “The large emerging market for PFAS removal and BLGO’s growing recognition of this opportunity should not be overlooked.” Ryan maintained his Buy rating on the stock on November 19th.
The Catalyst: Increased Awareness of Health Risks
According to a report by Markets and Markets, the PFAS filtration market is expected to grow from $2.13 billion in 2025 to $2.99 billion in 2030, with a compound annual growth rate (CAGR) of 7% during this period. This growth is largely due to increased awareness of the serious health and environmental risks posed by PFAS.
These chemicals are very persistent and have been linked to cancer, hormonal imbalances, immune system effects, and other chronic health problems. As a result, governments around the world, particularly in North America, Europe and parts of Asia, are introducing stricter regulations on PFAS levels in drinking water, industrial wastewater and consumer products. These regulatory actions are prompting communities and industries to invest in PFAS removal technologies. Key drivers of market growth include increasing health and environmental concerns, stricter environmental regulations and increasing demand for clean and safe drinking water.
According to Grand View Research, regulatory agencies such as the U.S. Environmental Protection Agency (EPA) and the European Chemicals Agency (ECHA) are enforcing stricter limits on PFAS levels in drinking water and pushing municipalities and industries to adopt advanced treatment technologies. Increased investment in wastewater infrastructure as well as technological advances in adsorption, membrane filtration and destruction processes are increasing market acceptance in industrial, commercial and municipal sectors.
“The market presents significant growth opportunities, driven by increasing investment in advanced remediation technologies and the emergence of sustainable treatment materials,” Grand View explained. “The increasing focus on green chemistry and circular economy principles is promoting the development of environmentally friendly adsorbents, regenerable resins and PFAS destruction methods such as plasma and electrochemical oxidation.”
The growth of public-private partnerships for large-scale pollution remediation and increasing demand for distributed and mobile treatment systems are creating new opportunities for solution providers, the report says. Additionally, Grand View highlighted the integration of digital monitoring tools and AI-driven analytics for real-time PFAS detection, improving operational efficiency and scalability of treatment solutions.
Ownership and share structure1
About 13.79% of BioLargo is owned by insiders and management. These include Chief Science Officer Kenneth Code with 8.17%, CEO Calvert with 3.3% and Director Jack Strommen with 1.56%.
About 0.04% is held by the institution First American Trust. The rest, 86%, comes from retail.
The market cap is $60.46 million, with about 313.76 million shares outstanding and about 270.51 million shares in the float. The trading price is between $0.32 and $0.14 within 52 weeks.
|
Would you like to be the first to find out something interesting? Life science tools and diagnostics, technology And Special situations Investment ideas? Sign in to receive this FREE Streetwise Reports' newsletter. |
Subscribe |
The information listed above was updated at the time of publication of this article and was compiled from information provided by the Company and various other data providers.